1-[2-(4-Nitrophenyl)ethyl]piperazin-2-one → 4-[2-(3-Fluoro-4-nitrophenyl)ethyl]-1-[2-(4-nitrophenyl)ethyl]piperazin-2-one
반응식
[N+:1]([C:4]1[CH:9]=[CH:8][C:7]([CH2:10][CH2:11][N:12]2[CH2:17][CH2:16][NH:15][CH2:14][C:13]2=[O:18])=[CH:6][CH:5]=1)([O-:3])=[O:2].[F:19][C:20]1[CH:21]=[C:22]([CH2:29][CH:30]=O)[CH:23]=[CH:24][C:25]=1[N+:26]([O-:28])=[O:27]>>[F:19][C:20]1[CH:21]=[C:22]([CH2:29][CH2:30][N:15]2[CH2:16][CH2:17][N:12]([CH2:11][CH2:10][C:7]3[CH:8]=[CH:9][C:4]([N+:1]([O-:3])=[O:2])=[CH:5][CH:6]=3)[C:13](=[O:18])[CH2:14]2)[CH:23]=[CH:24][C:25]=1[N+:26]([O-:28])=[O:27]참가 물질
3
실험 절차
The title compound was prepared from 1-[2-(4-Nitrophenyl)ethyl]piperazin-2-one and (3-Fluoro-4-nitrophenyl)acetaldehyde following essentially the same procedure as Example 6. The product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA). LC-MS (IE, m/z): 417 [M+1]+.
후처리
- customThe product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA)